Action RLMD RELMADA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Relmada Therapeutics, Inc.

Actions

RLMD

US75955J4022

Temps Différé Nasdaq
Autres places de cotation
 20:25:46 27/06/2024 		Varia. 5j. Varia. 1 janv.
3 USD +0,33 % Graphique intraday de Relmada Therapeutics, Inc. -1,32 % -27,54 %
12/06 Transcript : Relmada Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 11:20 AM
05/06 RELMADA THERAPEUTICS, INC. : Goldman Sachs opte pour une recommandation de vente ZM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
PR
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
PR
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PR
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
PR
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
PR
Relmada Therapeutics Provides Corporate Update
PR
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
PR
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS, Neuro Summit
AQ
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology Congress
AQ
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
PR
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
PR
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
PR
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
PR
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
PR
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
PR
RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD
PR
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RLMD
  4. Actualités Relmada Therapeutics, Inc.
  5. Communiqués